AMALFi - Active Monitoring for Atrial Fibrillation
Important update regarding the COVID-19 outbreak – April update
Due to the COVID-19 outbreak and consequent disruptions to our usual working practices, there may be some delay in receiving a response from the AMALFI study team.
We apologise if you have volunteered to take part but have not yet heard back from us. We will try to respond to you as quickly as possible but we are aware that this is taking longer than usual, so please bear with us.
If you have received a Zio Patch, you should wear it as planned and then return it using the box provided. We might take longer than expected to write back to you and your GP with the results of the monitoring report. However, we will still be able to access these results remotely, and can inform your GP if there is any reason for concern.
Although this temporary disruption may delay the completion of the study, it is not expected to affect the safety of our participants or the integrity of the study.
Thank you once again for your interest in this important medical study.
The AMALFI study has been designed and is run by researchers at the University of Oxford's Clinical Trial Service Unit and Epidemiological Studies Unit (CTSU) and the Division of Cardiovascular Medicine, which are world-leading centres for this type of work.
The study is led by Professor Louise Bowman and Professor Barbara Casadei and involves cardiology and General Practice specialists as well as partnership work with many other local doctors, nurses and healthcare professionals.
This study will look at the possible benefits of screening people using a new Zio Patch monitor to detect atrial fibrillation. Half of the people in this study will wear the patch and half will not, so we can compare the Zio Patch to the usual medical care people receive on the NHS. The patch is used just once and worn continuously for two weeks.
Results regarding the presence or absence of AF and other clinically relevant findings will be sent to GPs who will then discuss any changes in treatment that might be needed. The study team will continue to monitor each participant's medical record for 5 years to see what happens to them during this time and whether the screening has made a difference.
AMALFI has been designed by the University of Oxford, who will run the study independently of any funders. The funding itself comes through the NHS funded Biomedical Research Centre and the National Institute for Health Research with additional support from iRhythm, who are donating the Zio Patches free of charge.